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Abstract
Background: Low muscle mass and function have been associated with poorer indicators of physical capability in older
people, which are in-turn associated with increased mortality rates. The growth hormone/insulin-like growth factor (GH/IGF)
axis is involved in muscle function and genetic variants in genes in the axis may influence measures of physical capability.
Methods: As part of the Healthy Ageing across the Life Course (HALCyon) programme, men and women from seven UK
cohorts aged between 52 and 90 years old were genotyped for six polymorphisms: rs35767 (IGF1), rs7127900 (IGF2),
rs2854744 (IGFBP3), rs2943641 (IRS1), rs2665802 (GH1) and the exon-3 deletion of GHR. The polymorphisms have previously
been robustly associated with age-related traits or are potentially functional. Meta-analysis was used to pool within-study
genotypic effects of the associations between the polymorphisms and four measures of physical capability: grip strength,
timed walk or get up and go, chair rises and standing balance.
Results: Few important associations were observed among the several tests. We found evidence that rs2665802 in GH1 was
associated with inability to balance for 5 s (pooled odds ratio per minor allele = 0.90, 95% CI: 0.82–0.98, p-value = 0.01,
n = 10,748), after adjusting for age and sex. We found no evidence for other associations between the polymorphisms and
physical capability traits.
Conclusion: Our findings do not provide evidence for a substantial influence of these common polymorphisms in the GH/
IGF axis on objectively measured physical capability levels in older adults.
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Introduction
Muscle mass declines with age [1,2] and low muscle mass and
function in older people have been associated with a range of
adverse outcomes [3], including poorer mobility [4], increased
disability [1,2] and higher mortality rates [5]. Low muscle mass
and area are also independently associated with lower levels of
objective measures of physical capability, the capacity to undertake
the physical tasks of daily living, including grip strength [6], ability
to balance [7] and to complete five chair stands [7]. Therefore,
understanding the contributors to the inter-individual variability of
muscle properties is important and may be relevant to the
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prevention of the adverse consequences of lower levels of physical
capability [8–10]. Variability attributed to the growth hormone/
insulin-like growth factor (GH/IGF) axis may also have the
potential to lead to the development of novel interventions [11].
The GH/IGF axis plays an important role in body growth and
composition [12]. IGF-I is produced in the liver in response to GH,
as well as in skeletal muscle, and plays an important role in muscle
growth and function [11–15], promoting and differentiating muscle
cells, together with IGF-II [13]. Of the six binding proteins, most of
IGF-I is bound to IGFBP-3 [12], which regulates the bioactivity of
IGF-I and is expressed in skeletal muscle [14], possibly having IGF-I
independent effects. Insulin receptor substrate 1 (IRS-1) interacts
with the IGF receptor [14] and is involved in regulating body size
[16]. The GH receptor is expressed throughout the body [12] and
knockout of the GHR gene in mice leads to a reduction in body and
muscle mass [17]. In addition to muscle function, the GH/IGF axis
is also believed to play a role in some cancers [16,18], longevity and
ageing [19–21]. Whilst evidence from small to moderately sized
investigations into the effects of the GH/IGF axis on muscle
properties and physical performance in humans has been mixed
[11,12], it has been hypothesised that polymorphisms in genes in the
GH/IGF axis may contribute to measures of muscle functioning
and physical capability, phenotypes that have been shown to be
partly heritable [22,23].
In genome-wide association studies (GWAS), single-nucleotide
polymorphisms (SNPs) around IGF1 have been associated with
height [24–26] and the C allele of rs35767 upstream of the gene
has been associated with increased fasting insulin and insulin
resistance risk [27] as well as lower levels of IGF-I [28–30]. There
is some evidence to suggest that SNPs in IGF2 are associated with
longevity [31], measures of adult body size [32–35], grip strength
[36], arm and leg strength [37], and post-exercise muscle damage
[38], and in a GWAS the A allele of rs7127900 near the gene has
been associated with increased risk of prostate cancer [39]. The A
allele of functional SNP rs2854744 in the promoter region of
IGFBP3 has been associated with higher levels of IGFBP-3 [18,40]
and may be associated with reduced breast and prostate cancer
risk [18]. Increased type 2 diabetes risk has been associated with
the C allele of rs2943641 near IRS1 in GWAS [41]. Studies of the
functional SNP rs2665802 (in GH1) [42] have found associations
between its minor allele and lower colorectal cancer risk [43] and
mortality risk in females [44]. The exon-3 deletion of GHR
(d3GHR) has been associated with response to GH administration
in short children [45] and is perfectly tagged by several SNPs in
Europeans [46], among which rs6873545 has a suggested
association with lung cancer [47]. We therefore examined the
associations between these polymorphisms and anthropometric
and physical capability traits in 13,364 men and women aged
between 52 and 90 years as part of the HALCyon (Healthy Ageing
across the Life Course; www.halcyon.ac.uk) programme, in what
we believe to be the largest investigation into polymorphisms in
the GH/IGF axis and physical capability.
Methods
Ethics Statement
Written informed consent was obtained from all participants.
Ethical approval for each study was obtained from the relevant
ethics committees.
Study Populations
The Medical Research Council National Survey of Health and
Development (NSHD) comprises participants sampled from all
births in a week in March 1946 and followed up since. In 1999, at
age 53 years, men and women were visited by a research nurse
and consent for DNA extraction was given by approximately 2900
members of the cohort. Details of the data collected and the
several phases of the study are available on the cohort’s website
(www.nshd.mrc.ac.uk) and elsewhere [48].
The English Longitudinal Study of Ageing (ELSA) comprises
men and women aged 50 years and over who originally
participated in the Health Survey for England in 1998, 1999 or
2001. Fieldwork began in 2002–03 (Phase I) with two-yearly
follow-ups and in 2004–05 (Phase II) blood samples were provided
by 6231 participants. Details of the cohort have been published
[49].
The Hertfordshire Cohort Study (HCS) consists of 2997
participants born 1931–39 and registered with a General
Practitioner in East, North or West Hertfordshire who attended
a clinic in 1994–2004 (Phase I). A second assessment took place in
2004–05 for participants in East Hertfordshire (Phase II). Further
details of study design, data collected and summaries of participant
characteristics have been published [50] and are available on its
website (www.mrc.soton.ac.uk/herts).
The Hertfordshire Ageing Study (HAS) comprises men and
women traced in 1994–95, the first follow-up (Phase I), of singleton
births from 1920–30 in North Hertfordshire. A total of 717
participants attended a clinic during which DNA was extracted. A
second follow-up took place in 2003–05 (Phase II). Details of the
recruitment, data collected and summaries of participant charac-
teristics have been described previously [51].
The Boyd Orr cohort is a historical cohort study based on
children surveyed in 1937–39 in English and Scottish districts.
Participants were followed-up for vital status via the NHS Medical
Information Research Service (MIRS) since 1948, with question-
naire administration to survivors in 1997–98 (Phase II) and a
research clinic visit in 2002–03 (Phase III), during which DNA was
extracted from 728 adults. Details of the study design and the data
collected have been described on its website (www.epi.bris.ac.uk/
boydorr) and elsewhere [52].
The Caerphilly Prospective Study (CaPS) recruited 2512 men
aged between 45 and 59 years in 1979–83 from the town of
Caerphilly, South Wales, and its surrounding villages. Blood
samples were collected at baseline and at each of the four follow-
ups (Phase II: 1984–88, Phase III: 1989–93, Phase IV: 1993–97
and Phase V: 2002–04.) Further details are available on the cohort’s
website (www.epi.bris.ac.uk/caerphilly/caerphillyprospectivestudy.
htm).
The Lothian Birth Cohort 1921 Study (LBC1921) participants
were all born in 1921 and completed an IQ assessment at age 11.
In 1999–2001 (Phase I) 550 79 year olds, living in and around
Edinburgh, attended a clinic. Details of the recruitment into the
study are available on its website (www.lothianbirthcohort.ed.ac.
uk) and have been published previously [53].
Genotyping and Quality Control
Genotyping for SNPs rs35767 (2C1245T, IGF1), rs7127900
(IGF2), rs2854744 (A-202C, IGFBP3), rs2943641 (IRS1) and
rs2665802 (T1663A/T1169A, GH1) for all cohorts, except
LBC1921, were carried out by KBioscience (www.kbioscience.
co.uk). Genotype information for rs7127900 (IGF2) and rs2943641
(IRS1) in LBC1921 came from a genome-wide scan performed on
the Illumina Human610-Quadv1 Chip (www.illumina.com) [54].
The d3GHR (exon-3 deletion of GHR) polymorphism resulted
from recombination between two near identical retroelements and
can therefore be genotyped using a ‘‘pseudo-SNP’’ assay for a
single nucleotide difference between the two alleles [55].
Genotyping for the d3GHR pseudo-SNP was performed by
GH/IGF Polymorphisms and Physical Capability
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KBioscience. Data quality was reviewed by assessing clustering
quality (using KBioscience software SNPviewer on their data), call
rates and deviation from Hardy-Weinberg equilibrium (HWE).
Where deviation from HWE was detected for a study based on the
hypothesis test, no exclusions were made due to the high quality of
the studies in this investigation and the consistent genotyping
methods used for the majority of the polymorphisms across the
studies [56].
Phenotypes
Anthropometry. Measurements were conducted either at
clinics, during a clinical interview in the home, or from self-report.
Body mass index (BMI kg/m2) was calculated as weight divided by
height squared. Waist-hip ratio (WHR) was defined as waist
circumference (cm) divided by hip circumference (cm) and was
measured in NSHD, ELSA, HCS, HAS, Boyd Orr and CaPS.
Physical Capability and Activity. Grip strength was
measured in NSHD, ELSA, HCS, HAS and LBC1921 using
electronic or hydraulic dynamometers, with the best measure used
in the analysis where more than one trial was conducted. Standing
balance tests were conducted in the studies, with participants’ eyes
open: flamingo [57], (stopped at 30 s) in NSHD, HCS, HAS, Boyd
Orr and CaPS, and side-by-side, semi-tandem and full tandem [58]
in ELSA. Poor standing balance was defined for this analysis as the
inability to complete 5 s. The timed get up and go test [59] was
carried out in HCS, HAS, Boyd Orr and CaPS and required
participants to get up from a chair, walk 3 m, turn, walk back, turn
and sit down. Timed walks over 2.44 m (8 feet) and 6 m were
carried out in ELSA and LBC1921 respectively. Speeds were
calculated for timed walks and get up and go, with the fastest speeds
used in the analysis where more than one trial was conducted.
Timed chair rises [60] involved asking participants to rise from a
chair and sit back down 5 times in ELSA, HCS and HAS, and 10
times in NSHD; the reciprocal of time taken in seconds6100 [61]
was used in the analysis. Levels of physical activity were derived
from self reported levels using questionnaires in NSHD, ELSA,
Boyd Orr, CaPS and LBC1921. Individuals were categorised as
‘physically active’ in this analysis if they engaged, at least once a
month, in at least moderate sport or activities in NSHD, Boyd Orr,
CaPS and LBC1921 or vigorous sport or activities in ELSA.
Statistical Methods
Where information on ancestry was collected, non-European
participants were excluded from the analyses in order to avoid
confounding from population stratification [62]. Within studies,
linear and logistic regression analyses were conducted on the
continuous and dichotomous traits within the cohorts respectively,
adjusting for sex in all studies except CaPS, and age in all studies
except NSHD and LBC1921. Analyses of physical capability
measures were repeated additionally adjusting for height and
weight. Due to the low frequency of individuals homozygous for
the T allele of rs35767 (n = 296, 2.3%), T allele of rs7127900
(n= 455, 3.5%) and the exon-3 deletion of GHR (n = 853, 6.5%),
dominant models were used for these polymorphisms in order to
avoid the presentation of tables containing cells with very low
frequencies in particular cohorts. Additive models were used for
rs2854744, rs2943641 and rs2665802 with genotypes coded as 0, 1
and 2 for the number of minor alleles. Likelihood ratio tests were
used to compare the fit of the additive models compared with the
full genotype model. For continuous traits, the normality of the
standardised residuals was inspected with distributional diagnostic
plots. Cook’s distances [63] were plotted against fitted values,
using a cut-off of four divided by sample size, to identify influential
outliers in the continuous phenotypes. For the harmonisation of
continuous traits that were used to obtain pooled estimates of the
genotypic effects, z-score units were calculated in each study by
subtracting the study mean and dividing by its standard
deviation. The overall mean for z-scores is 0 and standard
deviation 1. Beta coefficients calculated on z-score units can be
reverted to the original scale by multiplying by an appropriate
standard deviation. Two-step [64] meta-analyses using a random-
effects model were performed to obtain pooled genotypic effects.
The I2 measure was used to quantify heterogeneity [65].
Additionally, within-study analyses of the physical capability
traits were stratified by physical activity, an indicator shown to
modify genotypic effects on anthropometric measures [66] and
the effects of rs2665802 on colorectal cancer risk [67]. Finally, the
calculation of z-scores, for the continuous traits, and the main
analyses were repeated in males and females separately. Quanto
[68] was used for power calculations. Reporting of the analyses
met the appropriate items of recommended checklists [69,70]. A
Table 1. Summary of Sex, Age and Minor Allele Frequencies by Cohort.
Cohort
Variable NSHD ELSA HCS HAS Boyd Orr CaPS LBC1921 Total
Number of participants 2618 5515 2902 551 397 867 514 13364
Male, % 50 46 53 59 45 100 41 52
Age* in years, median (range) 53 65 (52–90+) 66 (59–73) 67 (63–73) 70 (64–82) 73 (65–83) 79 (77–80) 65 (52–90+)
Minor Allele Frequencies
rs35767 (IGF1) 0.16 0.15 0.15 0.16 0.16 0.16 0.14 0.15
rs7127900 (IGF2) 0.18 0.18 0.20 0.21 0.19 0.17 0.19 0.19
rs2854744 (IGFBP3) 0.47 0.45 0.46 0.45 0.42 0.46 0.42 0.45
rs2943641 (IRS1) 0.36 0.35 0.35 0.36 0.38 0.35 0.35 0.35
rs2665802 (GH1) 0.41 0.40 0.41 0.41 0.39 0.40 0.41 0.41
d3GHR 0.26 0.27 0.27 0.24 0.27 0.28 0.26 0.27
Numbers of participants represent those with available data for at least one anthropometric or physical capability phenotype and at least one genotype.
*Age at phase from which the majority of variables are taken, i.e. Boyd Orr: III; CaPS: V; ELSA: II; HAS: I; HCS: I; LBC1921: I; NSHD: 1999 Collection. CaPS: Caerphilly
Prospective Study; ELSA: English Longitudinal Study of Ageing; HAS: Hertfordshire Ageing Study; HCS: Hertfordshire Cohort Study; NSHD: National Survey of Health and
Development.
doi:10.1371/journal.pone.0029883.t001
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two-tailed significance level of p,0.05 was used as evidence of
statistical significance. Statistical analysis was performed in Stata
11.1 (StataCorp LP).
Results
Cohort Summaries and Genotyping Quality
Relevant genotypic and phenotypic data were available for a
total of 13,364 adults aged between 52 and 90 years old (Table 1).
The call rates were high, exceeding 95% across the studies for all
polymorphisms. The HWE condition was met for rs35767,
rs7127900, rs2854744, rs2943641 and rs2665802 in all studies
(p-values.0.09) except for rs7127900 in HAS (p-value = 0.001)
and rs2665802 in LBC1921 (p-value = 0.02). Whilst the HWE
condition was met for d3GHR in ELSA, HAS, Boyd Orr and
CaPS (p-values.0.09) it was not met in two of the larger studies,
NSHD (p-value = 0.02) and HCS (p-value = 0.04), and was
borderline in LBC1921 (p-value = 0.06), with the number of d3/
d3 individuals under-represented.
Associations between Genotypes and Phenotypes
In ELSA, the study with the widest age range, genotype
frequencies in those under 70 years were compared with those
over 70 years; the T allele of rs2943641 (IRS1) was more common
among those over 70 (chi-squared p-value = 0.0059). Associations
with age group were not observed for the other polymorphisms (p-
values.0.1; data not shown).
Figure 1 and Tables S1, S2, S3, S4, S5, S6 show the associations
between the polymorphisms and height, weight, BMI and WHR
adjusting for age and sex. From the pooled analyses there was
evidence for associations between d3GHR and weight (p-val-
ue=0.048) and BMI (p-value=0.005), with individuals with at least
one exon-3 deletion allele having lower weight and BMI compared
with individuals retaining both copies of the exon (Figure S1 and S2).
There was also a trend among individuals carrying the exon-3
deletion to have a lower WHR (p-value=0.07) and for rs2854744-A
(IGFBP3) to be associated with shorter height (p-value= 0.08). There
was no evidence for other associations between the polymorphisms
and anthropometric measures (p-values.0.1).
Figure 1. Pooled Results of Associations between Genotypes and Measures of Anthropometry. Adjusted for age and sex. Models used:
rs35767 (IGF1)- (C/T+T/T) vs. C/C; rs7127900 (IGF2)- (C/T+T/T) vs. C/C; rs2854744 (IGFBP3- per minor (A) allele; rs2943641 (IRS1)- per minor (T) allele;
rs2665802 (GH1)- per minor (T) allele; d3GHR- (fl/d3+d3/d3) vs. fl/fl. fl: full length; d3: exon-3 deletion.
doi:10.1371/journal.pone.0029883.g001
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Figure 2 and Tables S1, S2, S3, S4, S5, S6 show that there was
no evidence for associations between any of the polymorphisms
and grip strength, timed get up and go/walks and timed chair rises
after adjusting for age and sex (p-values.0.1). Similarly, there
were no associations after additionally adjusting for height and
weight (p-values.0.1; data not shown).
The associations between the polymorphisms and poor balance,
adjusting for age and sex, are presented in Figure 3 and Tables S1,
S2, S3, S4, S5, S6. There was evidence for an association with
SNP rs2665802 (GH1) (p-value = 0.01), with the minor allele
associated with increased ability to balance (Figure S3). The
association remained after additional adjustment for height and
weight (p-value = 0.02; data not shown). There was no evidence
for associations with the other polymorphisms after adjusting for
age, sex (p-values.0.5), height and weight (p-values.0.4; data not
shown).
In only a relatively small number of tests did the full genotype
model represent a significantly better fit than the per allele model
(indicated in Tables S3, S4, S5).
Within NSHD, ELSA, Boyd Orr, CaPS and LBC1921, there
was little evidence that the genotypic effects for the physical
capability traits differed between the physically active and inactive.
Interactions were only observed in Boyd Orr for rs2854744 with
balance (p-value=0.04) and in ELSA for rs2943641 with grip
strength (p-value= 0.03); however, the genotypic effects were not
significant in either group in ELSA, whilst an association was
observed with balance in the physically inactive group in Boyd Orr.
Investigations by Sex
Figures S4 and S5 present the pooled associations between the
polymorphisms and the anthropometric traits adjusting for age in
males and females, respectively. There was evidence for a sex
difference between rs2943641 (IRS1) and height (p-value = 0.03 for
heterogeneity between males and females) with the T allele being
associated with greater height in females but not males (Figure S6).
There was no evidence for any other sex differences between the
polymorphisms and anthropometric traits (heterogeneity p-val-
ues.0.1).
Pooled associations between the polymorphisms and the
physical capability traits, adjusting for age, in males and females
are presented in Figures S7 to S9. There was no evidence for sex
differences (heterogeneity p-values.0.1), except for rs35767 (IGF1)
Figure 2. Pooled Results of Associations between Genotypes and Grip Strength, TGUG and Chair Rises. Adjusted for age and sex. Timed
chair rises on reciprocal of time taken in sec6100. Models used: rs35767 (IGF1)- (C/T+T/T) vs. C/C; rs7127900 (IGF2)- (C/T+T/T) vs. C/C; rs2854744
(IGFBP3- per minor (A) allele; rs2943641 (IRS1)- per minor (T) allele; rs2665802 (GH1)- per minor (T) allele; d3GHR- (fl/d3+d3/d3) vs. fl/fl. fl: full length;
d3: exon-3 deletion.
doi:10.1371/journal.pone.0029883.g002
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and chair rises (heterogeneity p-value = 0.03) where the genotypic
effects were in opposite directions, though not achieving statistical
significance in either sex (Figure S10).
Discussion
We examined associations between six common polymorphisms
in the GH/IGF axis and measures of anthropometric and physical
capability phenotypes in seven UK cohorts comprising a total of
13,364 adults aged between 52 and 90 years. To our knowledge
this is the largest investigation into polymorphisms in the axis and
physical capability. The polymorphisms chosen are either
functional or have been robustly associated with age-related
phenotypes in GWAS. Among the 48 genotype association tests
conducted in the main analysis there were few important
associations observed. We found evidence for associations between
d3GHR and anthropometry, with carriers of at least one exon-3
deletion having lower weight, BMI and a trend towards lower
WHR. After adjusting for age and sex we found evidence for an
association with physical capability for only one of the polymor-
phisms, with the minor allele of rs2665802 (GH1) being associated
with increased ability to balance for at least 5 s. On the whole, the
associations for physical capability were similar in males and
females, between the physically active and inactive and after
additionally adjusting for height and weight. These findings
suggest that these polymorphisms are not important contributors
to physical capability in older adults.
GWAS in Asian populations have found associations between
SNPs around IGF1, including rs35767, and height [25,26].
However, to-date, little evidence has emerged from GWAS
supporting highly significant associations between common
polymorphisms in the six genes that we investigated in the
GH/IGF axis and measures of anthropometry in Europeans
[71,72]. Although, it is possible that SNPs in these six genes may
significantly modify the effects on lean body mass of SNPs in
other genes that are relevant to the GH/IGF axis [73]. We
observed no association between rs35767 (IGF1) and measures of
body size, consistent with other studies on European populations
[27,74]. A previous investigation in elderly men and women
found no consistent associations between rs35767 (IGF1) and
measures of body composition and walk times, grip strength and
timed chair stand [75]. We did not observe poorer measures of
physical capability among carriers of the risk allele for prostate
cancer for rs7127900 near IGF2 [39]. Other smaller studies had
found no association between rs2854744 (IGFBP3) and measures
of adult body size in women of European ancestry (n = 1702)
[76], or muscle phenotypes in response to strength training in
older adults (n = 128) [77]. Unlike a previous study (n = 454) [44],
we did not observe associations between rs2665802 (GH1) and
height in either sex, nor were associations reported with height or
BMI elsewhere (sample sizes ranged between 293 and 1003)
[43,78,79]. Our results suggested that the minor allele of
rs2665802 (GH1) was associated with better ability to balance
for at least 5 s. The allele has also been associated with lower
colorectal cancer [43] and mortality risk in females [44], though
the null findings observed for the other measures of physical
capability would suggest that rs2665802 (GH1) does not
substantially influence measures of physical capability. In
Figure 3. Pooled Results of Associations between Genotypes and Poor Balance. Adjusted for age and sex. Poor balance defined as inability
to complete the Flamingo test for 5 s in Boyd Orr, HAS, HCS, NSHD and CaPS, and 5 s of the tandem test in ELSA. Models used: rs35767 (IGF1)- (C/T+T/
T) vs. C/C; rs7127900 (IGF2)- (C/T+T/T) vs. C/C; rs2854744 (IGFBP3- per minor (A) allele; rs2943641 (IRS1)- per minor (T) allele; rs2665802 (GH1)- per
minor (T) allele; d3GHR- (fl/d3+d3/d3) vs. fl/fl. fl: full length; d3: exon-3 deletion.
doi:10.1371/journal.pone.0029883.g003
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addition, a study of 169 athletes and 155 controls suggests that it
is not associated with athletic status [80]. Our meta-analysis
provided some evidence for lower weight and BMI among
carriers of the exon-3 deletion of GHR. Although few specific
investigations into the d3GHR polymorphism on population-
based studies of adults have been conducted, smaller studies have
found no associations with measures of body size (sample sizes
ranged between 100 and 831) [46,81,82]; however, one study
observed associations between its haplotypic block and BMI [46].
We therefore contacted the GIANT Consortium [83] to look up
associations between tag SNPs of d3GHR and BMI. No
associations were observed in per minor allele models for BMI
for any of the five available SNPs, for example, for rs4590183 the
data suggested a p-value of 0.98 in an analysis of 123,863
participants, suggesting our observed associations for d3GHR
with weight and BMI were false positives.
It is an important finding that this investigation does not provide
evidence for a substantial role of these common polymorphisms in
the GH/IGF axis and measures of physical capability given the
statistical power of this multi-cohort study. Sample size calcula-
tions for the quantitative traits for 80% power at the 5%
significance level estimated that around 7000 individuals would
be required to detect a beta coefficient of 0.07 z-score units under
a dominant model for a polymorphism with a MAF of 0.19 or for
0.05 z-score units under an additive model using a MAF of 0.35.
For example, there was sufficient power to detect a difference in
grip strength of around 0.8 kg under a dominant model for
rs7127900 (IGF2), assuming a standard deviation of 11. This
allows the inference that any associations between the polymor-
phisms and physical capability traits are very small.
Deviation from the HWE condition was detected for d3GHR in
two of the larger studies, NSHD and HCS. However, the only
suggested associations for d3GHR were with weight and BMI,
which were found to be in opposite directions for these studies
(Table S6, Figure S1 and S2), indicating that, although exclusion is
not recommended [56], excluding these two studies would not
substantially affect the overall pooled results. Furthermore, whilst
we observed four deviations from HWE altogether, around two
statistically significant tests would be expected given the 42 (6
polymorphisms67 studies) HWE tests performed.
Whilst the choice of polymorphisms within our candidate genes
were primarily based on robust associations observed with age-
related traits [18,27,39,41], or functional evidence [42], additional
polymorphisms in these genes may be useful for exploring further
the influence of common polymorphisms in the GH/IGF axis on
measures of physical capability.
Conclusion
The results of this large, multi-cohort investigation do not
support the hypothesis that these common polymorphisms in the
GH/IGF axis contribute substantially to objectively measured
physical capability in older adults.
Supporting Information
Figure S1 Meta-analysis for the Associations between
d3GHR Genotype and Weight. Adjusted for age and sex.
Coefficients based on z-scores. fl: full length; d3: exon-3 deletion.
(TIF)
Figure S2 Meta-analysis for the Associations between
d3GHR Genotype and BMI. Adjusted for age and sex.
Coefficients based on z-scores. fl: full length; d3: exon-3 deletion.
(TIF)
Figure S3 Meta-analysis for the Associations between
rs2665802 (GH1) Genotype and Poor Balance. Adjusted for
age, sex. Poor balance defined as inability to complete the
Flamingo test for 5 s in Boyd Orr, HAS, HCS, NSHD and CaPS,
and 5 s of the tandem test in ELSA.
(TIF)
Figure S4 Summary of Pooled Results of Associations
between Genotypes and Measures of Anthropometry in
Males. Adjusted for age. Models used: rs35767 (IGF1)- (C/T+T/
T) vs. C/C; rs7127900 (IGF2)- (C/T+T/T) vs. C/C; rs2854744
(IGFBP3- per minor (A) allele; rs2943641 (IRS1)- per minor (T)
allele; rs2665802 (GH1)- per minor (T) allele; d3GHR- (fl/d3+d3/
d3) vs. fl/fl. fl: full length; d3: exon-3 deletion.
(TIF)
Figure S5 Summary of Pooled Results of Associations
between Genotypes and Measures of Anthropometry in
Females. Adjusted for age. Models used: rs35767 (IGF1)- (C/
T+T/T) vs. C/C; rs7127900 (IGF2)- (C/T+T/T) vs. C/C;
rs2854744 (IGFBP3- per minor (A) allele; rs2943641 (IRS1)- per
minor (T) allele; rs2665802 (GH1)- per minor (T) allele; d3GHR-
(fl/d3+d3/d3) vs. fl/fl. fl: full length; d3: exon-3 deletion.
(TIF)
Figure S6 Meta-analysis for the Associations between
rs2943641 (IRS1) Genotype and Height by Sex. Adjusted
for age. Coefficients based on z-scores.
(TIF)
Figure S7 Summary of Pooled Results of Associations
between Genotypes and Grip Strength, Timed Get Up &
Go and Chair Rises in Males. Adjusted for age. Timed chair
rises on reciprocal of time taken in sec 6100. Models used:
rs35767 (IGF1)- (C/T+T/T) vs. C/C; rs7127900 (IGF2)- (C/
T+T/T) vs. C/C; rs2854744 (IGFBP3- per minor (A) allele;
rs2943641 (IRS1)- per minor (T) allele; rs2665802 (GH1)- per
minor (T) allele; d3GHR- (fl/d3+d3/d3) vs. fl/fl. fl: full length; d3:
exon-3 deletion.
(TIF)
Figure S8 Summary of Pooled Results of Associations
between Genotypes and Grip Strength, Timed Get Up &
Go and Chair Rises in Females. Adjusted for age. Timed
chair rises on reciprocal of time taken in sec6100. Models used:
rs35767 (IGF1)- (C/T+T/T) vs. C/C; rs7127900 (IGF2)- (C/
T+T/T) vs. C/C; rs2854744 (IGFBP3- per minor (A) allele;
rs2943641 (IRS1)- per minor (T) allele; rs2665802 (GH1)- per
minor (T) allele; d3GHR- (fl/d3+d3/d3) vs. fl/fl. fl: full length; d3:
exon-3 deletion.
(TIF)
Figure S9 Summary of Pooled Results of Associations
between Genotypes and Poor Balance by Sex. Adjusted for
age. Poor balance defined as inability to complete the Flamingo
test for 5 s in Boyd Orr, HAS, HCS, NSHD and CaPS, and 5 s of
the tandem test in ELSA. Models used: rs35767 (IGF1)- (C/T+T/
T) vs. C/C; rs7127900 (IGF2)- (C/T+T/T) vs. C/C; rs2854744
(IGFBP3- per minor (A) allele; rs2943641 (IRS1)- per minor (T)
allele; rs2665802 (GH1)- per minor (T) allele; d3GHR- (fl/d3+d3/
d3) vs. fl/fl. fl: full length; d3: exon-3 deletion.
(TIF)
Figure S10 Meta-analysis for the Associations between
rs35767 (IGF1) Genotype and Timed Chair Rises by Sex.
Adjusted for age. Timed chair rises on reciprocal of time taken in
sec6100. Coefficients based on z-scores.
(TIF)
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